BioSpace News Archive

MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI”), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David Urso, chief operating officer and general counsel, effective immediately.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (more commonly known as a heart attack)

BVI has developed a ‘Patient Pack’ in collaboration with ophthalmic surgeons and administrators to reduce the complexity and concerns in bringing patients back

Jazz Pharmaceuticals is proud to support the American Heart Association’s sleep health educational content Research demonstrates that disrupted sleep and sleep disorders are associated with a higher risk of cardiovascular and cardiometabolic diseases, including obesity, diabetes, heart attack, stroke and coronary artery disease [15-September-2020] DUBLIN , Se

NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor’s use as Foundational Therapy PDUFA Goal Date - April 29, 2021 [15-September-2020] FREMONT, Calif. , Sept. 15, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people w

Proscia®, a leading provider of digital pathology solutions, has introduced the third generation of its Concentriq® platform to help life sciences organizations accelerate the lengthy drug development process.

The collaboration will standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization that could one day be extrapolated to thresholds considered sufficient to confer immunity. Standardization across manufacturers is also expected to improve patient care by enabling long-term antibody level comparison. TARRYTOWN, N.Y.--( BUSINESS WIRE )-- Siemens Healthineers announced today a

TYME’s Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs The Phase II Prostate Cancer study demonstrated that oral SM-88 (racemetyrosine) was associated with disease control while maintaining QOL; More than 450,000 of these patient cases annually in U.S. alone Based on study results, SM-88 may have a clinically meaningful role in postponi

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Accelera

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4 th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform. DiaMedica Therapeutics management is scheduled to meet with investor